Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel artificial intelligence (AI) framework to make predictions on potential synergistic anti-cancer drug combinations for both therapeutic and toxic effects. Many of the biotech sector's biggest wins of late have come through drug combinations, utilizing the strengths and downplaying the weaknesses of available therapies, including recent developments from Oncolytics Biotech Inc. Merck, Amgen Inc., Bristol-Myers Squibb Company, and Mirati Therapeutics, Inc. For example, significant work is being done on behalf of women in America, where breast cancer is known to be the second leading cause of death from cancer--with an estimated 42,000 deaths in the US in 2020. The problem also persists in China, where breast cancer is now estimated to be the largest subtype of cancer among women, with over 416,000 cases and over 117,000 deaths in 2020. As part of the fight against breast cancer, a multinational front is moving forward between US-based Oncolytics Biotech Inc. and Chinese multinational clinical-stage biopharma developers Adlai Nortye.